CombinatoRx' Prednisolone/Dipyridamole Combination abstract to be presented at the ACR 2009

NewsGuard 100/100 Score

CombinatoRx, Incorporated (NASDAQ: CRXX) today announced that its abstract entitled, “CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results”, has been accepted for oral presentation at the American College of Rheumatology (ACR) 2009 Annual Meeting in Philadelphia on October 20, 2009. The abstract can be accessed online at http://www.rheumatology.org/annual/index.aspwww.eular.org by clicking on "search abstracts" and entering the author name or abstract number.

Oral Presentation:

  • Abstract #1943: “CRx-102 (Prednisolone/Dipyridamole Combination) Enhances Glucocorticoid (GC) Efficacy and Reduces Adverse Effects in OA Therapy: 3-12 Month Results,” Huttner, et.al, Tuesday, October 20, 2009: 5:15 PM Room 108 B, Pennsylvania Convention Center.

Source CombinatoRx, Incorporated.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative malaria prodrug targets liver, enhances efficacy while reducing toxicity, preclinical studies show